Teva Pharmaceutical Industries EBITDA 2010-2024 | TEVA

Teva Pharmaceutical Industries EBITDA for the quarter ending September 30, 2024 was $0.210B, a 66.56% decline year-over-year.

  • Teva Pharmaceutical Industries 2023 EBITDA was 1.586B, a 278.4% decline from 2022.
  • Teva Pharmaceutical Industries 2022 EBITDA was -0.889B, a 129.2% decline from 2021.
  • Teva Pharmaceutical Industries 2021 EBITDA was 3.045B, a 251.19% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Teva Pharmaceutical Industries EBITDA 2010-2024 | TEVA

  • Teva Pharmaceutical Industries 2023 EBITDA was 1.586B, a 278.4% decline from 2022.
  • Teva Pharmaceutical Industries 2022 EBITDA was -0.889B, a 129.2% decline from 2021.
  • Teva Pharmaceutical Industries 2021 EBITDA was 3.045B, a 251.19% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Dr Reddy's Laboratories (RDY)$12B
BridgeBio Pharma (BBIO)$4.3B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.1B
Supernus Pharmaceuticals (SUPN)$2B
Taysha Gene Therapies (TSHA)$434M
Personalis (PSNL)$261M
Assembly Biosciences (ASMB)$98M
Sol-Gel Technologies (SLGL)$12M
Evoke Pharma (EVOK)$7M
Teligent (TLGT)$0M